

Michele Simbolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2809765/publications.pdf>

Version: 2024-02-01

83
papers

5,656
citations

186265
28
h-index

98798
67
g-index

86
all docs

86
docs citations

86
times ranked

11078
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance. <i>Biomedicines</i> , 2022, 10, 277.	3.2	4
2	Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. <i>Familial Cancer</i> , 2022, 21, 441-451.	1.9	3
3	Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1283.	4.1	3
4	Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series. <i>Current Oncology</i> , 2022, 29, 178-185.	2.2	3
5	Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature. <i>Pathologica</i> , 2022, 114, 164-169.	3.4	1
6	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. <i>Human Pathology</i> , 2022, 128, 124-133.	2.0	6
7	Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 45-51.	1.7	1
8	Molecular Biology of Neuroendocrine Tumors. , 2021, , 37-53.		0
9	Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival. <i>Cancers</i> , 2021, 13, 903.	3.7	20
10	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. <i>ESMO Open</i> , 2021, 6, 100032.	4.5	19
11	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 1741.	2.4	5
12	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 650293.	2.8	26
13	Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 663489.	2.8	3
14	Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis. <i>Diagnostics</i> , 2021, 11, 762.	2.6	47
15	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. <i>Cancers</i> , 2021, 13, 2054.	3.7	10
16	H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 987-996.	2.8	12
17	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. <i>Cells</i> , 2021, 10, 2685.	4.1	4
18	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 200.	5.2	10

#	ARTICLE	IF	CITATIONS
19	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1095-1105.	3.4	13
20	Diffuse gliomas in patients aged 55% years or over: A suggestion for <i>IDH</i> mutation testing. <i>Neuropathology</i> , 2020, 40, 68-74.	1.2	23
21	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. <i>Cancers</i> , 2020, 12, 2283.	3.7	41
22	Exosomal miRNA signatures of pancreatic lesions. <i>BMC Gastroenterology</i> , 2020, 20, 137.	2.0	25
23	30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, S10.	1.2	0
24	Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. <i>Updates in Surgery</i> , 2020, 72, 119-128.	2.0	9
25	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	27.8	1,966
26	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	2.2	4
27	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , 2019, 9, 12286.	3.3	27
28	Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?. <i>Hpb</i> , 2019, 21, 1648-1655.	0.3	10
29	Exploring the molecular and biological background of lung neuroendocrine tumours. <i>Journal of Thoracic Disease</i> , 2019, 11, S1194-S1198.	1.4	2
30	Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases. <i>Annals of Oncology</i> , 2019, 30, v574.	1.2	0
31	Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma. <i>Neuropathology</i> , 2019, 39, 474-478.	1.2	7
32	Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. <i>Cancers</i> , 2019, 11, 1279.	3.7	23
33	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	1.1	73
34	Comparative Lesions Analysis Through a Targeted Sequencing Approach. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	0
35	P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCIpe Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, S728.	1.1	0
36	Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. <i>Cancer Immunology Research</i> , 2019, 7, 12-28.	3.4	21

#	ARTICLE	IF	CITATIONS
37	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. <i>Pancreas</i> , 2019, 48, 70-76.	1.1	11
38	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. <i>Journal of Pathology</i> , 2019, 247, 123-134.	4.5	32
39	Combined adenocarcinoma and atypical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components. <i>Diagnostic Histopathology</i> , 2018, 24, 120-123.	0.4	10
40	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 567-577.	2.8	64
41	Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. <i>Journal of Hepatology</i> , 2018, 68, 959-969.	3.7	254
42	Ampulla of Vater Carcinoma. <i>Annals of Surgery</i> , 2018, 267, 149-156.	4.2	35
43	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. <i>Gastroenterology</i> , 2018, 154, 1066-1079.e5.	1.3	94
44	Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. <i>Annals of Oncology</i> , 2018, 29, viii511-viii512.	1.2	0
45	Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models. <i>Annals of Oncology</i> , 2018, 29, viii665.	1.2	1
46	P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S734-S735.	1.1	0
47	Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. <i>Oncotarget</i> , 2018, 9, 9661-9671.	1.8	36
48	Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 709-717.	2.8	40
49	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018, 214, 1675-1680.	2.3	1
50	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	1.1	74
51	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	3.6	18
52	Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 1385-1395.	3.4	13
53	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , 2018, 39, 971-980.	2.8	48
54	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7119.	3.3	39

#	ARTICLE	IF	CITATIONS
55	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 542-542.	1.6	1
56	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	3.3	44
57	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
58	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S266-S267.	1.1	4
59	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1243-1249.	1.2	25
60	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for <i>TERT</i> , <i>RB1</i> , <i>MEN1</i> and <i>KMT2D</i> . <i>Journal of Pathology</i> , 2017, 241, 488-500.	4.5	179
61	Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target. <i>Annals of Oncology</i> , 2017, 28, vi57.	1.2	0
62	Co-existence of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20631-e20631.	1.6	0
63	New genomic landscapes and therapeutic targets for biliary tract cancers. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 707-718.	3.0	5
64	Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model. <i>Annals of Oncology</i> , 2016, 27, iv7.	1.2	0
65	HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity. <i>Journal of Hepatology</i> , 2016, 64, S559.	3.7	0
66	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. <i>Scientific Reports</i> , 2016, 6, 22982.	3.3	16
67	Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 1699-1707.	1.5	76
68	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. <i>Oncotarget</i> , 2016, 7, 1076-1083.	1.8	68
69	Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers. , 2016, , .		0
70	Detection of EGFR alterations in circulating tumor DNA of non-small cell lung cancer by digital PCR and Next Generation Sequencing. <i>Annals of Oncology</i> , 2015, 26, vi79.	1.2	0
71	483 The Concept of Perihilar Cholangiocarcinoma Is Still Valid? Analysis of Clinicopathological Features and Mutational Genes Profiling in a Series of 56 Cases. <i>Gastroenterology</i> , 2015, 148, S-1111.	1.3	0
72	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2015, 26, 469-473.	1.4	1

#	ARTICLE	IF	CITATIONS
73	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. <i>Cancer Discovery</i> , 2015, 5, 1296-1313.	9.4	145
74	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 18.	1.5	31
75	Molecular Portrait of Resected Gastric Cancer (Rgc) with Next Generation Sequencing (Ngs) According to a Clinical Biological Risk Model Considering Fhit, Apc and Her-2 Overexpression. <i>Annals of Oncology</i> , 2014, 25, iv219.	1.2	0
76	Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e63-e66.	1.6	47
77	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , 2014, 17, 442-449.	5.3	52
78	High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 73-78.	2.8	66
79	Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. <i>PLoS ONE</i> , 2014, 9, e104979.	2.5	35
80	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014, 5, 2839-2852.	1.8	171
81	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	21.4	564
82	DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples. <i>PLoS ONE</i> , 2013, 8, e62692.	2.5	209
83	Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT. , 2011, , .		0